Subscribe
Logo small
Search

Dr Agnieszka Jagiełło-Gruszfeld: Trastuzumab derukstecan has a chance to be used on a large scale in the treatment of breast cancer

MedExpress Team

Piotr Wójcik

Published Dec. 15, 2022 11:37

Dr Agnieszka Jagiełło-Gruszfeld: Trastuzumab derukstecan has a chance to be used on a large scale in the treatment of breast cancer - Header image
– At the congress in San Antonio, the results of research in HER2 positive breast cancer were presented. They confirmed the role of trastuzumab derukstecan in the treatment. It has been shown that it extends the overall survival time in patients who received this drug in the treatment of metastatic breast cancer in the second line of treatment - said in an interview with Medexpress Dr. Agnieszka Jagiełło-Gruszfeld, head of the conservative department of the Breast Cancer and Reconstructive Surgery Clinic in National Institute of Oncology.

 

The congress in San Antonio has recently ended. This is probably the most important event dedicated to breast cancer. Are there any interesting, hopeful reports from there?

Yes, there has been a lot of talk about trastuzumab deruxtekan, which is now recommended for the treatment of HER2+ breast cancer. The results of the research were also shown in the so-called HER2-low cancer, which has not yet been considered for treatment with anti-HER2 drugs. The concept of HER2 low cancer has appeared recently, because we have been talking about it for about two years. This is a subtype in which estrogen receptors are present or absent, ...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.